Abbott Laboratories (NYSE:ABT – Get Free Report) was upgraded by equities researchers at Leerink Partners from a “market perform” rating to an “outperform” rating in a note issued to investors on Thursday, MarketBeat reports. The brokerage currently has a $124.00 price objective on the healthcare product maker’s stock. Leerink Partners‘s target price would suggest a potential upside of 20.44% from the stock’s current price.
Several other analysts have also recently commented on ABT. UBS Group decreased their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their target price for the stock from $119.00 to $127.00 in a report on Friday, October 2nd. BTIG Research decreased their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a research report on Thursday, October 22nd. Finally, Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $119.04.
View Our Latest Research Report on ABT
Abbott Laboratories Stock Down 0.9%
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the business posted $1.30 earnings per share. Equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.
Insider Activity
In related news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the sale, the executive vice president directly owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.46% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp grew its position in shares of Abbott Laboratories by 0.6% in the third quarter. State Street Corp now owns 81,431,110 shares of the healthcare product maker’s stock valued at $8,047,837,000 after purchasing an additional 504,876 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $1,603,607,000. Deutsche Bank AG increased its stake in shares of Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after purchasing an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company’s stock.
Latest Abbott Laboratories News
These are some of the ABT news items that stood out recently:
- Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
- Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
- Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article
About Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Further Reading
- Five stocks we like better than Abbott Laboratories
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
